BioCryst Pharmaceuticals announced the appointment of Robert A. Ingram as Chairman of its Board of Directors. Following the company’s annual meeting Ingram will serve as Chairman of the Board of Directors and George B. Abercrombie will serve as a member of the Company’s Board of Directors.
“I am grateful for George’s leadership of the Board over the last four years and look forward to his continued participation on our Board,” Chief Executive Officer, Jon Stonehouse said. “We are very fortunate to have Bob Ingram take the reins in leading our Board as there are very few people with his long and successful record of leadership in the pharmaceutical industry, as well as his extensive experience on publicly-listed company boards. I look forward to working closely with him as we continue to build a successful rare disease company.”
“During my time on the Board, I have been impressed with BioCryst’s dedication to patients with rare disease and the pursuit of highly innovative therapies. I am very excited to help guide BioCryst through what promises to be an exciting time as it initiates Phase 3 development and prepares for commercialization of BCX7353,” Robert A. Ingram, Chairman of the Board of the Directors said.
Ingram was appointed to the Board of Directors in August 2015. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO and Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline (GSK) and served as Vice Chairman Pharmaceuticals of GSK until January 1, 2010. He joined Hatteras Venture Partners, a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine, as a General Partner in January 2007 and continues in that role. Mr. Ingram currently serves as Lead Director of Cree, a manufacturer of semiconductor light-emitting diode materials and devices, as Chairman of the Board of Novan, a pharmaceutical company, as Chairman of Viamet Pharmaceuticals, a private company focused on anti-infective research, and as a Director of PhaseBio Pharmaceuticals, a private clinical-stage biopharmaceutical company. Ingram also serves as a member of the Board of Directors of HBM Healthcare Investments, a publicly traded Swiss investment company, and of Malin Corporation, a publicly traded life sciences company based in Ireland.